Evaluation of DTRAX Graft in Patients With Cervical Degenerative Disc Disease
Primary Purpose
Cervical Spondylosis, Cervical Radiculopathy, Cervical Degenerative Disc Disease
Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
DTRAX Graft
Sponsored by
About this trial
This is an interventional treatment trial for Cervical Spondylosis
Eligibility Criteria
Inclusion Criteria:
Subject diagnosed with DDD in C3-C7, defined as follows:
Radiographically (at least one):
- degenerated disc on MRI;
- decreased disc height on plain film, CT or MRI; and/or
- disc herniation, as demonstrated by CT or MRI.
Clinically: radicular symptoms (at least one):
- arm/shoulder pain;
- decreased reflexes;
- decreased strength; and/or
- decreased sensation.
Subject has single-level disease, OR multi-level disease demonstrated radiographically, and confirmed to be symptomatic by one of the following methods:
- Selective nerve root block, OR
- EMG, OR
- Distinctive clinical examination.
- Subject has dynamic stenosis relieved by traction and made worse by a Spurlings maneuver.
- Subject is 35-80 years of age, inclusive.
- Subject is unresponsive to 6 weeks conservative, nonoperative treatment, or has the presence of progressive symptoms or signs of nerve root compression in face of combined nonoperative management.
- Preoperative NDI score of ≥ 30.
- Preoperative neck pain and arm pain score of ≥ 6 on Neck and Arm Pain Scales.
- Patient is a male or non-pregnant, non-lactating female.
- Female patients of child-bearing potential, including those who have had a tubal ligation, but excluding those who have not experienced a menstrual period for at least two years, must have a negative urine pregnancy test at Screening.
- Patient must voluntarily provide written, informed consent.
- Subject is able to meet the proposed follow-up schedule.
- Subject is able to follow the postoperative management program.
Exclusion Criteria:
- Subject has severe osteopenia, osteoporosis, osteomalacia, spinal metastases, or metabolic bone disease OR the level of BMD is a T score of -2.5 or below OR patient has sustained a vertebral compression or nontraumatic hip or wrist fracture.
- Subject has overt or active spinal and/or systemic infection.
- Subject has spondylolisthesis ≥ 3.5mm or rotator subluxation.
- Subject has cervical myelopathy.
- Subject has a chronic pain syndrome.
- Subject has radicular findings with major motor impairment.
- Subject has a condition that requires postoperative medications that interfere with fusion or the stability of the implant, such as steroids.
- Subject is mentally incompetent.
- Subject is a prisoner.
- Subject is pregnant.
- Subject abuses alcohol or drugs.
- Subject has a cervical spinal condition other than symptomatic cervical disc disease requiring surgical treatment at the involved level.
- Subject has insulin dependent diabetes.
- Subject has chronic or acute renal failure or prior history of renal disease.
- Subject has fever at the time of surgery, defined as > 38.5 degrees C.
- Subject has documented allergy or intolerance to stainless steel, titanium, or a titanium alloy.
- Subject has received drugs which may interfere with bone metabolism within two weeks prior to the planned date of DTRAX surgery.
- Subject has history of an endocrine or metabolic disorder known to affect osteogenesis .
- Subject has had treatment with an investigational therapy within 28 days prior to DTRAX surgery or such treatment is planned during the 16 weeks following implantation of DTRAX Graft.
- Subject is involved in spinal litigation or Workmen's Compensation claim.
- Subject is obese, defined as body mass index (BMI) > 35.
- Patient has psychiatric history, head injury or any other condition, which, in the Investigator's opinion, would prevent the patient from complying with postoperative follow-up visits.
Sites / Locations
- Office of Dr. Brian Andrews, Neurosurgery
- Neurospine Institute Medical Group
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
DTRAX graft
Arm Description
Outcomes
Primary Outcome Measures
Gather clinical outcome data on DTRAX Graft.
Clinical outcome data will be collected using the Neck Disability Index (NDI), Visual Analogue Scale (VAS), and a quality of life questionnaire.
Secondary Outcome Measures
Safety information will be evaluated by collecting the type, frequency, severity, device, and procedure-relatedness of adverse events.
Full Information
NCT ID
NCT01616719
First Posted
June 7, 2012
Last Updated
March 2, 2020
Sponsor
Providence Medical Technology, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT01616719
Brief Title
Evaluation of DTRAX Graft in Patients With Cervical Degenerative Disc Disease
Official Title
Evaluation of DTRAX Graft in Patients With Cervical Degenerative Disc Disease
Study Type
Interventional
2. Study Status
Record Verification Date
March 2020
Overall Recruitment Status
Withdrawn
Why Stopped
study was never started due to lack of resources
Study Start Date
May 2012 (Anticipated)
Primary Completion Date
February 2014 (Anticipated)
Study Completion Date
February 2015 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Providence Medical Technology, Inc.
4. Oversight
5. Study Description
Brief Summary
DTRAX Graft is used to relieve nerve pressure in the neck in order to provide relief for Cervical Degenerative Disc Disease. This study is being conducted to determine the effectiveness of the graft, and to find out whether or not it provides better results or faster healing than traditional ways of performing surgery for Cervical Degenerative Disc Disease.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cervical Spondylosis, Cervical Radiculopathy, Cervical Degenerative Disc Disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
DTRAX graft
Arm Type
Other
Intervention Type
Device
Intervention Name(s)
DTRAX Graft
Intervention Description
DTRAX Graft is an allograft implant inserted to support spinal fusion.
Primary Outcome Measure Information:
Title
Gather clinical outcome data on DTRAX Graft.
Description
Clinical outcome data will be collected using the Neck Disability Index (NDI), Visual Analogue Scale (VAS), and a quality of life questionnaire.
Time Frame
Baseline throughout 12 months post-operatively
Secondary Outcome Measure Information:
Title
Safety information will be evaluated by collecting the type, frequency, severity, device, and procedure-relatedness of adverse events.
Time Frame
Baseline throughout 12 months post-operatively
10. Eligibility
Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subject diagnosed with DDD in C3-C7, defined as follows:
Radiographically (at least one):
degenerated disc on MRI;
decreased disc height on plain film, CT or MRI; and/or
disc herniation, as demonstrated by CT or MRI.
Clinically: radicular symptoms (at least one):
arm/shoulder pain;
decreased reflexes;
decreased strength; and/or
decreased sensation.
Subject has single-level disease, OR multi-level disease demonstrated radiographically, and confirmed to be symptomatic by one of the following methods:
Selective nerve root block, OR
EMG, OR
Distinctive clinical examination.
Subject has dynamic stenosis relieved by traction and made worse by a Spurlings maneuver.
Subject is 35-80 years of age, inclusive.
Subject is unresponsive to 6 weeks conservative, nonoperative treatment, or has the presence of progressive symptoms or signs of nerve root compression in face of combined nonoperative management.
Preoperative NDI score of ≥ 30.
Preoperative neck pain and arm pain score of ≥ 6 on Neck and Arm Pain Scales.
Patient is a male or non-pregnant, non-lactating female.
Female patients of child-bearing potential, including those who have had a tubal ligation, but excluding those who have not experienced a menstrual period for at least two years, must have a negative urine pregnancy test at Screening.
Patient must voluntarily provide written, informed consent.
Subject is able to meet the proposed follow-up schedule.
Subject is able to follow the postoperative management program.
Exclusion Criteria:
Subject has severe osteopenia, osteoporosis, osteomalacia, spinal metastases, or metabolic bone disease OR the level of BMD is a T score of -2.5 or below OR patient has sustained a vertebral compression or nontraumatic hip or wrist fracture.
Subject has overt or active spinal and/or systemic infection.
Subject has spondylolisthesis ≥ 3.5mm or rotator subluxation.
Subject has cervical myelopathy.
Subject has a chronic pain syndrome.
Subject has radicular findings with major motor impairment.
Subject has a condition that requires postoperative medications that interfere with fusion or the stability of the implant, such as steroids.
Subject is mentally incompetent.
Subject is a prisoner.
Subject is pregnant.
Subject abuses alcohol or drugs.
Subject has a cervical spinal condition other than symptomatic cervical disc disease requiring surgical treatment at the involved level.
Subject has insulin dependent diabetes.
Subject has chronic or acute renal failure or prior history of renal disease.
Subject has fever at the time of surgery, defined as > 38.5 degrees C.
Subject has documented allergy or intolerance to stainless steel, titanium, or a titanium alloy.
Subject has received drugs which may interfere with bone metabolism within two weeks prior to the planned date of DTRAX surgery.
Subject has history of an endocrine or metabolic disorder known to affect osteogenesis .
Subject has had treatment with an investigational therapy within 28 days prior to DTRAX surgery or such treatment is planned during the 16 weeks following implantation of DTRAX Graft.
Subject is involved in spinal litigation or Workmen's Compensation claim.
Subject is obese, defined as body mass index (BMI) > 35.
Patient has psychiatric history, head injury or any other condition, which, in the Investigator's opinion, would prevent the patient from complying with postoperative follow-up visits.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bruce McCormack, M.D.
Organizational Affiliation
Neurospine Institute Medical Group
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Brian Andrews, M.D.
Organizational Affiliation
Office of Dr. Brian Andrews, Neurosurgery
Official's Role
Principal Investigator
Facility Information:
Facility Name
Office of Dr. Brian Andrews, Neurosurgery
City
San Francisco
State/Province
California
ZIP/Postal Code
94114
Country
United States
Facility Name
Neurospine Institute Medical Group
City
San Francisco
State/Province
California
ZIP/Postal Code
94115
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Evaluation of DTRAX Graft in Patients With Cervical Degenerative Disc Disease
We'll reach out to this number within 24 hrs